100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond
OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition
How Systemic Therapy Is Reshaping Breast Cancer Care in 2026
Small-Molecule Inhibitors in NSCLC: A 2026 Practical Guide to Drug Interactions and Toxicity
Sri Navaratnam Named Candidate for UICC Board of Directors 2026–2028
Michail Ignatiadis: Grateful for Hosting Session on Metastatic Breast Cancer at MAMMÔ 2026
Jason Mouabbi: Is T-DM1 Still Useful after T-DXd in HER2+ Metastatic Breast Cancer
Oncopeptides Reports Blood-Brain Barrier Penetration in Glioblastoma INSULA Study
Enter the Recurrence Score and clinical context to view the RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
Our calculators apply published formulas as precisely as we can. Even so, no formula captures every detail of a real patient. Use the result as one input to your own assessment, not the final word.
